CI has extended its recovery to $303.35, up nearly 6% on the week, and the underlying data now tells a cleaner bullish setup than it did seven days ago — with shorts continuing to exit and options traders holding their call-heavy stance.
The most notable shift since last week's note is in short positioning. Short interest has fallen roughly 18% over the past seven days to 2.3% of free float — a meaningful reduction for a position that was already modest. The exit has been swift: the short book shrank from around 7.3 million shares in early July to just over 6 million now. Borrow conditions offer no friction to that unwind. Availability is extraordinarily loose at over 7,300% — meaning shares available to lend dwarf those already borrowed by a vast margin — and the cost to borrow a negligible 0.51%. There is simply no mechanical pressure keeping shorts in the trade.
Options traders are not second-guessing the move. The put/call ratio has held near 0.41, well below its 20-day average of 0.47 and close to the 52-week low of 0.35. That call-heavy lean has been remarkably consistent across the past two weeks, even as the stock has added another $17. The ORTEX short score has quietly eased to 34.3 from 37.4 at the start of the month — a direction that aligns with the short covering story rather than contradicting it. Positioning looks decidedly light rather than crowded.
The Street's constructive bias has firmed up modestly. Bernstein raised its target to $381 on July 9, maintaining Outperform, and the consensus target sits at $341 — implying roughly 12% upside from current levels. That's a narrower gap than it was a month ago, when the stock was trading in the $280s. The bull case centres on Cigna's exit from the Exchange business sharpening focus on commercial self-funding arrangements and Evernorth's services integration. Bears point to execution risk around healthcare cost management and potential margin pressure as Evernorth transitions away from rebate-based models. Deutsche Bank and Barclays both moved to neutral in May, keeping a cautious minority on the Street, but the majority remain positively rated with targets clustered in the $330-$400 range. The PE multiple at around 8.8x is undemanding relative to history, and the EV/EBITDA of roughly 7x compares favourably across managed care.
Among peers, CNC added nearly 4% on the week and ELV rose close to 2%, suggesting broad sector support rather than a CI-specific move. UNH was the outlier, slipping 0.7%, while MD fell sharply — down more than 10% — highlighting that not all health services names are participating equally in the recovery.
The July 30 earnings print is now the central event. Both prior results in this snapshot produced a next-day decline of between 3% and 4%, so the market's current call-heavy positioning will face a direct test. What to watch between now and then is whether the PCR holds near its lows or starts creeping back toward its 20-day average — any rotation back toward puts would signal that the recent optimism is fading before the number even drops.
See the live data behind this article on ORTEX.
Open CI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
